Further studies, combining the compounds used in this study with current conventional T-ALL therapy, and in-vivo studies on animal models, are required to provide a better insight on the importance of CB2 and TRPV1 in leukemia, to investigate the precise molecular mechanism of these antitumor activities and whether this co-administration could be effectively applied in clinical practice. Here, CNR2 is linked to acute lymphoblastic leukemia.